The following is a summary of “Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data,” published in the November 2023 issue of Allergy and Clinical Immunology by Adame et al.
Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and intolerance to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) are all parts of aspirin-exacerbated respiratory disease (AERD). Atherosclerotic cardiovascular diseases (ASCVD) are more likely to happen to people who have asthma. However, more information is needed to show a link between AERD and ASCVD. For a study, researchers sought to look into the link between AERD and the risk of getting ASCVD later on. To find people with AERD, they made a program and checked it against patient records at their home hospital.
A national insurance claims database was queried with this method to get information for a study that looked back at a group of people over time. Demographic and disease data were gathered to do the probability matching.
The results were analyzed in several different ways. It was found that 571 patients had AERD, 3909 had asthma, CRSwNP, and were not allergic to aspirin or NSAIDs (group 1), and 75,050 had asthma, CRS without nasal polyps, and were not allergic to aspirin or NSAIDs (group 2). After taking into account other factors, AERD was significantly linked to ASCVD, including serious ASCVD, compared to groups 1 and 2, no matter how bad the asthma was.
People who have AERD have a higher chance of ASCVD than people who have asthma and CRSwNP or CRS without nasal polyps. It showed how important it was to look for ASCVD early and think about using aspirin desensitization or a different antiplatelet drug when someone has AERD and ASCVD at the same time.
Source: sciencedirect.com/science/article/abs/pii/S2213219823007857
